PEPG

PEPG

PepGen Ltd

Net 19.76%top 1%Rev โ€”top 1%Net income grew 100% of years1Y
Hold

PepGen Ltd develops oligonucleotide therapeutics targeting severe neuromuscular and neurologic diseases. Its leading product candidates include PGN-EDODM1 and FREEDOM2-DM1, both in Phase 2 trials for myotonic dystrophy type 1 in the U.S.

โš•๏ธ Healthcare NASDAQ Listed 2022 $ USD
$1,000 invested 1 year ago โ†’$2,544today

Score Overview

1 Year
Scoreโ€”
Net Growth19.76%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-4.11%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

PepGen Ltd fundamental performance

Across PepGen Ltd's full reported history, from 2022 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 69M to -$ 89M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.90โ€”
1 Year2025-08-12
$ 1.14154.39%
All Time2022-05-06
$ 12.89-77.50%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 71M$ 117M
2025$ 0.00-$ 89M$ 148M
2024$ 0.00-$ 89M$ 120M
2023$ 0.00-$ 78M$ 110M
IPO2022$ 0.00-$ 69M$ 181M

Explore beyond PEPG

You're looking at PepGen Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies